enGene names new board chairman ahead of planned BLA filing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil rebounds, Middle East tensions simmer
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
July 16, 2026 8:00 AM EDTMichael Heffernan assumes the role of Chairman of the Board
Dr. Richard Glickman to step down
Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026
Initiation of BLA submission for detalimogene planned for 2H 2026
Potential FDA approval of detalimogene in 2027
BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for... More
